2VF0 Stock Chart & Stats
€0.03
<€0.01(16.67%)
At close: 4:00 PM EDT
€0.03
<€0.01(16.67%)
Day’s Range― - ―
52-Week Range€0.02 - €0.08
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.87M
Enterprise Value€14.23
Total Cash (Recent Filing)€196.46K
Total Debt (Recent Filing)€3.56M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Nov 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding211,441,440
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.66
Price to Book (P/B)-2.96
Price to Sales (P/S)0.00
P/FCF Ratio-3.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Regenerative-medicine PlatformA focused development strategy around autologous regenerative medicine gives Hemostemix a defined therapeutic identity and a clear clinical objective. Concentrating resources on vascular regeneration and ACP-01 may support disciplined research, regulatory execution, and intellectual-property development over the next several quarters.
Defined Lead Clinical ProgramACP-01 addresses a specific high-severity vascular use case and is designed around a measurable biological objective: improving blood flow. A clearly defined lead program can provide strategic focus for clinical development, regulatory work, and potential partnering discussions as evidence accumulates.
Debt Is Below Its Prior PeakDebt not rising steadily, and remaining below the 2024 peak, is a relative balance-sheet positive even though the capital structure is weak overall. This may reduce incremental leverage pressure and preserve some flexibility while the company continues clinical and regulatory activities.
Bears Say
Pre-commercial Revenue ProfileNo revenue across the reported periods confirms that Hemostemix remains pre-commercial and has not yet demonstrated recurring operating income from its therapy portfolio. Continued dependence on development rather than product sales leaves future progress tied to clinical, regulatory, and commercialization milestones.
Persistent And Widening LossesPersistent losses, including renewed widening in 2025 and the latest TTM period, indicate limited operating leverage while research and development continue. Without revenue to absorb fixed and clinical costs, this pattern can prolong funding dependence and constrain the company’s ability to scale independently.
Negative Equity And Cash BurnNegative equity combined with worsening operating and free-cash-flow burn signals substantial financial fragility. The company must continue funding activities despite limited balance-sheet resources, increasing reliance on external capital and raising the risk that future financing could dilute existing shareholders.
Hemostemix News
2VF0 FAQ
What was Hemostemix Inc’s price range in the past 12 months?
Hemostemix Inc lowest stock price was €0.02 and its highest was €0.08 in the past 12 months.
What is Hemostemix Inc’s market cap?
Hemostemix Inc’s market cap is €9.87M.
When is Hemostemix Inc’s upcoming earnings report date?
Hemostemix Inc’s upcoming earnings report date is Nov 27, 2026 which is in 77 days.
How were Hemostemix Inc’s earnings last quarter?
Hemostemix Inc released its earnings results on Aug 31, 2026. The company reported -€0.002 earnings per share for the quarter.
Is Hemostemix Inc overvalued?
According to Wall Street analysts Hemostemix Inc’s price is currently Overvalued.
Does Hemostemix Inc pay dividends?
Hemostemix Inc does not currently pay dividends.
What is Hemostemix Inc’s EPS estimate?
Hemostemix Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hemostemix Inc have?
Hemostemix Inc has 211,441,440 shares outstanding.
What happened to Hemostemix Inc’s price movement after its last earnings report?
Hemostemix Inc reported an EPS of -€0.002 in its last earnings report. Following the earnings report the stock price went down -6.25%.
Which hedge fund is a major shareholder of Hemostemix Inc?
Currently, no hedge funds are holding shares in DE:2VF0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hemostemix Inc
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.